Soleno Therapeutics (SLNO) Total Current Liabilities (2013 - 2026)
Soleno Therapeutics (SLNO) reported Total Current Liabilities of $58.0 million for Q1 2026, up 269.01% year-over-year from $15.7 million in Q1 2025, and down 5.4% on a QoQ basis from $61.4 million in Q4 2025.
Soleno Therapeutics (SLNO) has 14 years of Total Current Liabilities data on file, last reported at $58.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 269.01% year-over-year to $58.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (up 269.01% YoY) and the FY2025 annual result came in at $61.4 million, up 227.32% from the prior year.
- Total Current Liabilities declined to $58.0 million in Q1 2026 per SLNO's latest filing, from $61.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $61.4 million in Q4 2025 and bottomed at $7.2 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $13.5 million (2024), against an average of $19.5 million.
- The widest annual swing landed in 2023, when Total Current Liabilities soared 294.89%; it then sank 48.39% in 2024.
- Tracing SLNO's Total Current Liabilities over 5 years: stood at $7.3 million in 2022, then jumped by 57.32% to $11.5 million in 2023, then soared by 62.95% to $18.7 million in 2024, then jumped by 227.32% to $61.4 million in 2025, then fell by 5.4% to $58.0 million in 2026.
- Per Business Quant, the three latest SLNO Total Current Liabilities figures stand at $58.0 million (Q1 2026), $61.4 million (Q4 2025), and $33.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 58.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.05 Mn |
| Dec 31, 2025 | 61.36 Mn |
| Sep 30, 2025 | 33.25 Mn |
| Jun 30, 2025 | 20.94 Mn |
| Mar 31, 2025 | 15.73 Mn |
| Dec 31, 2024 | 18.75 Mn |
| Sep 30, 2024 | 14.96 Mn |
| Jun 30, 2024 | 9.15 Mn |
| Mar 31, 2024 | 13.46 Mn |
| Dec 31, 2023 | 11.51 Mn |
| Sep 30, 2023 | 28.99 Mn |
| Jun 30, 2023 | 8.80 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | 7.31 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | 7.25 Mn |
| Mar 31, 2022 | 7.31 Mn |
| Dec 31, 2021 | 8.01 Mn |
| Sep 30, 2021 | 9.04 Mn |
| Jun 30, 2021 | 8.36 Mn |
| Mar 31, 2021 | 9.51 Mn |
| Dec 31, 2020 | 8.62 Mn |
| Sep 30, 2020 | 8.00 Mn |
| Jun 30, 2020 | 8.36 Mn |
| Mar 31, 2020 | 7.29 Mn |
| Dec 31, 2019 | 4.96 Mn |
| Sep 30, 2019 | 3.45 Mn |
| Jun 30, 2019 | 2.86 Mn |
| Mar 31, 2019 | 2.25 Mn |
| Dec 31, 2018 | 1.88 Mn |
| Sep 30, 2018 | 2.51 Mn |
| Jun 30, 2018 | 1.95 Mn |
| Mar 31, 2018 | 1.94 Mn |
| Dec 31, 2017 | 1.73 Mn |
| Sep 30, 2017 | 1.73 Mn |
| Jun 30, 2017 | 2.12 Mn |
| Mar 31, 2017 | 2.17 Mn |
| Dec 31, 2016 | 1.71 Mn |
| Sep 30, 2016 | 1.78 Mn |
| Jun 30, 2016 | 1.90 Mn |
| Mar 31, 2016 | 2.58 Mn |
| Dec 31, 2015 | 3.19 Mn |
| Sep 30, 2015 | 6.03 Mn |
| Jun 30, 2015 | 13.35 Mn |
| Mar 31, 2015 | 1.06 Mn |
| Dec 31, 2014 | 1.29 Mn |
| Sep 30, 2014 | 1.60 Mn |
| Dec 31, 2013 | 14.18 Mn |